Effect of Hyperhomocysteinemia on Clinical Outcome and Hemorrhagic Transformation After Thrombolysis in Ischemic Stroke Patients

Yun Luo 1, Hang Jin 1, Zhen-Ni Guo 2, Peng Zhang 1, Li-Yue Zhang 1, Jie Chen 1, Yao Yu 1, Yan Wang 1, Jie Liu 1, Qian-Yan He 1, Xin Sun 1* and Yi Yang 1*

1 Department of Neurology, Stroke Center, The First Hospital of Jilin University, Chang Chun, China, 2 Department of Neurology, Neuroscience Center, The First Hospital of Jilin University, Chang Chun, China

Background and Purpose: Hyperhomocysteinemia (Hhcy) is a well-known risk factor for ischemic stroke. However, the role of Hhcy in the clinical outcome of ischemic stroke has not been fully elucidated. In addition, previous studies have found that Hhcy was implicated in the disruption of the blood-brain barrier, which may increase the risk of hemorrhagic transformation (HT) after thrombolysis. Thus, the aim of this study was to investigate the effect of Hhcy on the clinical outcome and HT after thrombolysis in ischemic stroke patients.

Methods: Patients who were diagnosed with ischemic stroke and received intravenous thrombolytic therapy between January 2016 and September 2018 were included in this study. Multivariate logistic regression analysis was used to assess the association between Hhcy, clinical outcome, and HT after thrombolysis. Furthermore, the potential interaction between Hhcy and hypertension on the clinical outcome and HT after thrombolysis was also assessed.

Results: Of 568 patients, 455 (80.1%) had Hhcy, 66 (11.6%) had HT, and 219 (38.6%) had poor outcome. Patients with Hhcy had a higher incidence of poor outcome than the patients with non-Hhcy (40.9 vs. 29.2%, \(p=0.022\)). However, there was no significant difference in the incidence of HT (11.9 vs. 10.6%, \(p=0.711\)) between patients with Hhcy and non-Hhcy. After adjustment for major covariates, multivariate logistic regression analysis disclosed that Hhcy was independently associated with increased risk of poor outcome (OR = 1.760; 95% CI: 1.069–2.896) but was not associated with the risk of HT (OR = 1.017; 95% CI: 0.495–2.087). In addition, we found no significant interaction between Hhcy and hypertension on the clinical outcome (\(p = 0.513\)) or HT (\(p = 0.170\)) after thrombolysis.

Conclusion: We found that Hhcy was an independent risk factor for poor outcome, but not an independent risk factor for HT after thrombolysis in ischemic stroke patients. In addition, there was no significant interaction of Hhcy and hypertension on the clinical outcome or HT after thrombolysis.

Keywords: hyperhomocysteinemia, ischemic stroke, recombinant tissue plasminogen activator, intravenous thrombolysis, clinical outcome, hemorrhagic transformation, symptomatic intracerebral hemorrhage
INTRODUCTION

Ischemic stroke accounts for 80–85% of all strokes and is one of the leading causes of mortality and disability in China (1). Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) is an effective treatment for ischemic stroke, but it also increases the risk of hemorrhagic transformation (HT) (2–4). Symptomatic intracerebral hemorrhage (sICH) is the most severe hemorrhagic complication of thrombolytic therapy, which is associated with early neurological deterioration and worsened clinical outcome (4).

Hyperhomocysteinemia (Hhcy) is a condition in which the plasma levels of homocysteine and related metabolites are elevated. Accumulating evidence has demonstrated that Hhcy is an independent risk factor for ischemic stroke (5). However, the role of Hhcy in the clinical outcome of ischemic stroke remains controversial. Some studies found that Hhcy was associated with increased risk of poor outcome in ischemic stroke patients (6–11), whereas some studies showed no significant association between Hhcy and the clinical outcome of ischemic stroke (12–16). In addition, previous studies have found that Hhcy was implicated in the disruption of the blood-brain barrier, and the breakdown of the blood-brain barrier played a critical role in the development of HT in ischemic stroke patients with thrombolysis (17, 18). Thus, the aim of this study was to investigate the effect of Hhcy on the clinical outcome and HT after thrombolysis in patients with ischemic stroke.

MATERIALS AND METHODS

This study was approved by the Ethics Review Committee of the First Hospital of Jilin University, and written informed consent was obtained from all participants or their direct relatives.

Participants

We consecutively recruited patients who were diagnosed with ischemic stroke and received intravenous thrombolysis with rtPA in our department between January 2016 and September 2018 for this study. The diagnosis of ischemic stroke was based on the clinical manifestations and signs, brain computed tomography (CT), and/or magnetic resonance imaging (MRI), as well as routine laboratory tests. Intravenous thrombolytic therapy was administrated within 4.5 h of onset for patients with ischemic stroke according to the recommendations of current guidelines and the decision of the treating physician (2, 3). After thrombolysis, all patients received standard medical treatment and general care in the comprehensive stroke center of our hospital. Patients who were lost on follow-up or missed data were excluded from this study. Patients were divided into Hhcy group and non-Hhcy group according to the levels of plasma homocysteine. A flow chart of the study is given in Figure 1.

Data Collection

Demographics, vascular risk factors, previous history of drugs, as well as clinical and follow-up information of participants were prospectively collected and recorded in a well-established system.
TABLE 1 | Patient characteristics between Hhcy group and non-Hhcy group.

| Variables                           | Total patients (n = 568) | non-Hhcy group (n = 455) | Hhcy group (n = 113) | p     |
|-------------------------------------|--------------------------|--------------------------|----------------------|-------|
| **Demographics**                    |                          |                          |                      |       |
| Age (year)                          | 62.2 ± 11.9              | 58.7 ± 10.6              | 63.1 ± 12.1          | 0.001 |
| Sex (male)                          | 418 (73.6%)              | 63 (55.8%)               | 355 (78.0%)          | 0.001 |
| **Vascular risk factors**           |                          |                          |                      |       |
| Cigarette smoking                   | 327 (57.6%)              | 53 (46.9%)               | 274 (60.2%)          | 0.010 |
| Alcohol consumption                 | 229 (40.3%)              | 45 (39.8%)               | 184 (40.4%)          | 0.905 |
| Atrial fibrillation                 | 100 (17.6%)              | 19 (16.8%)               | 81 (17.8%)           | 0.805 |
| Coronary heart disease              | 88 (15.5%)               | 17 (15.0%)               | 71 (15.6%)           | 0.883 |
| Hypertension                        | 338 (59.5%)              | 66 (58.4%)               | 272 (59.8%)          | 0.790 |
| Diabetes mellitus                   | 353 (62.1%)              | 75 (64.4%)               | 278 (61.1%)          | 0.301 |
| Previous stroke                     | 123 (21.7%)              | 26 (23.0%)               | 97 (21.3%)           | 0.696 |
| **Previous history of drugs**       |                          |                          |                      |       |
| Antihypertensive drugs              | 175 (30.8%)              | 26 (23.0%)               | 149 (32.7%)          | 0.045 |
| Hypoglycemic agents/insulin         | 76 (13.4%)               | 24 (21.2%)               | 52 (11.4%)           | 0.006 |
| Statins                             | 5 (0.9%)                 | 2 (1.8%)                 | 3 (0.7%)             | 0.260 |
| Anti-thrombotic agents              | 67 (11.8%)               | 15 (13.3%)               | 52 (11.4%)           | 0.586 |
| **Baseline parameters**             |                          |                          |                      |       |
| NIHSS score                         | 9 (5-13)                 | (4-12)                   | 9 (5-13)             | 0.334 |
| SBP (mmHg)                          | 157.8 ± 26.5             | 161.7 ± 27.9             | 156.9 ± 26.1         | 0.081 |
| DBP (mmHg)                          | 90 (80–100)              | 92 (82–100)              | 90 (79–100)          | 0.268 |
| Blood glucose (mmol/L)              | 7.02                     | 7.63                     | 6.88                 | 0.001 |
| Homocysteine level (µmol/L)         | 13.5                     | 8.6                      | 14.8                 | 0.001 |
| **Treatment**                       |                          |                          |                      |       |
| Time to treat (hour)                | 3.0 (2.3–3.8)            | 3.1 (2.3–3.9)            | 3.0 (2.3–3.8)        | 0.321 |
| Low-dose thrombolysis               | 157 (27.6%)              | 29 (25.7%)               | 128 (28.1%)          | 0.600 |
| Bridging therapy                    | 54 (9.5%)                | 8 (7.1%)                 | 46 (10.1%)           | 0.326 |
| **Characteristics of infarct**       |                          |                          |                      |       |
| Cortex                              | 214 (37.7%)              | 33 (29.2%)               | 181 (39.8%)          | 0.038 |
| Subcortex                           | 407 (71.7%)              | 81 (71.7%)               | 326 (71.6%)          | 0.994 |
| Thalamus                            | 63 (11.1%)               | 10 (8.8%)                | 53 (11.6%)           | 0.396 |
| Brainstem                           | 93 (16.4%)               | 24 (21.2%)               | 69 (15.2%)           | 0.118 |
| Cerebellum                          | 38 (6.7%)                | 7 (6.2%)                 | 31 (6.8%)            | 0.814 |
| Infarct volume (mL)                 | 20.1                     | 20.0                     | 20.3                 | 0.048 |
|                               (10.0–40.1)   |                         | (9.8–39.6)               | (10.1–40.3)          |       |
| **Outcome**                         |                          |                          |                      |       |
| HT                                  | 66 (11.6%)               | 12 (10.6%)               | 54 (11.9%)           | 0.711 |
| sICH                                | 10 (1.8%)                | 1 (0.9%)                 | 9 (2.0%)             | 0.695 |
| Poor outcome                        | 219 (38.6%)              | 33 (29.2%)               | 186 (40.9%)          | 0.022 |

Hhcy, hyperhomocysteinemia; NIHSS, National Institute of Health Stroke Scale; SBP, systolic blood pressure; DBP, diastolic blood pressure; HT, hemorrhagic transformation; sICH, symptomatic intracerebral hemorrhage.

database. All information was obtained by trained staff through a standard questionnaire. Cigarette smoking was defined as having smoked at least 1 cigarette per day for 1 year or more (19). Alcohol consumption was defined as consuming 1 or more alcoholic drinks per day during the last year (19). Atrial fibrillation was defined as having a history of atrial fibrillation or a clinical diagnosis of atrial fibrillation during hospitalization (20). Coronary heart disease was defined as having a history of coronary heart disease or a clinical diagnosis of coronary heart disease during hospitalization. Hypertension was defined as having a history of hypertension, taking oral antihypertensive drugs, or having a clinical diagnosis of hypertension during hospitalization (20). Diabetes mellitus was defined as having a history of diabetes mellitus, taking oral hypoglycemic agents/insulin, or having a clinical diagnosis of diabetes mellitus during hospitalization (20). Dyslipidemia was defined as having a history of any types of dyslipidemia, taking oral antidyospidemic drugs, or having at least one of the following findings during hospitalization: Total cholesterol ≥5.18 mmol/L, triglycerides ≥1.70 mmol/L, low-density lipoprotein cholesterol ≥3.37 mmol/L, and high-density lipoprotein cholesterol <1.04 mmol/L (20, 21). Previous stroke was defined as having a history of transient ischemic attack, ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage (20). Previous history of drugs was defined as taking certain drugs regularly before admission. Plasma homocysteine levels were measured in the fasting state within 24 h after admission. Total homocysteine level ≥10 µmol/L was defined as Hhcy, which was recommended by the American Heart Association and the American Stroke Association Council on stroke (22, 23). Based on the dose of rtPA, intravenous thrombolysis was classified as standard-dose (0.9 mg/Kg) thrombolysis and low-dose (0.6 mg/Kg) thrombolysis. Bridging therapy was defined as receiving mechanical thrombectomy after intravenous thrombolysis. The characteristics of cerebral infarct were evaluated on the brain CT/MRI after thrombolysis. Infarct locations were divided into cortex, subcortex, thalamus, brainstem, and cerebellum, as previously reported (24). Infarct volume was measured on brain CT/diffusion-weighted MRI by ITK-SNAP 3.6.0 (25).

**Outcome**

The clinical outcome was assessed at 3 months by modified Rankin Scale (mRS) with a score ranging from 0 (no symptoms) to 6 (death). We defined mRS scores ≥3 as a poor outcome and mRS scores ≤2 as a favorable outcome. HT was defined as any visible hemorrhage on brain CT or MRI 22–36 h after thrombolysis. sICH was defined as a HT that led to death or neurological deterioration with an increase of 4 or more on the National Institute of Health Stroke Scale (NIHSS) scores (26).

**Statistical Analysis**

The data were analyzed by Statistical Program for Social Sciences version 22.0 (SPSS, IBM, West Grove, PA, USA). Continuous variables were expressed as means and standard deviation if the data was normally distributed, and vice
versa by median and interquartile range. Categorical variables were expressed as frequency and percentage. The intergroup difference was compared using Student's \( t \)-test or Mann–Whitney test for continuous variables and the chi-squared test or Fisher's exact test for categorical variables. For exploring the effect of Hhcy on the clinical outcome and HT after thrombolysis, we first conducted univariate analysis to compare baseline factors associated with clinical outcome and HT. The variates with a \( p \)-value < 0.1 in the univariate analysis were included in multivariate logistic regression models as the major covariates. Then, we conducted multivariate logistic regression analysis to assess the association between Hhcy, clinical outcome, and HT after thrombolysis, and odd ratios (ORs) and 95% confidence intervals (95% CIs) were used to evaluate the risk of poor outcome and HT. Furthermore, we also assessed the potential interaction between Hhcy and hypertension on the clinical outcome and HT after thrombolysis. All statistical tests were two-tailed, and \( p < 0.05 \) was considered statistically significant.

RESULTS

Overall Characteristics of Study Participants

A total of 618 patients were screened for this study, of which 23 patients were lost for follow-up, 12 patients missed the data of brain CT/MRI after thrombolysis, and 15 patients did not receive the examination of plasma homocysteine. Finally, 568 patients (418 men and 150 women) were included, and the overall characteristics of participants are shown in Table 1. The mean age was 62.2 \( \pm \) 11.9 years. The median NIHSS score on admission was 9 (interquartile range, 5–13). The median time to treat was 3.0 h (interquartile range, 2.3–3.8 h). Previous history of drugs included antihypertensive drugs, hypoglycemic agents/insulin, statins, and anti-thrombotic agents. More than a quarter of participants received low-dose thrombolysis, and about 10% of patients underwent mechanical thrombectomy after intravenous thrombolysis. Of 568 patients, 455 (80.1%) had Hhcy, 66 (11.6%) had HT, 10 (1.8%) had sICH, and 219 (38.6%) had poor outcome.

Patient Characteristics Between Hhcy Group and Non-Hhcy Group

The patient characteristics between Hhcy group and non-Hhcy group are compared in the Table 1. We found that patients with Hhcy were usually older and had a lower baseline blood glucose level than patients with non-Hhcy. In addition, patients with Hhcy had a higher proportion of male and cigarette smoking but a lower prevalence of diabetes mellitus than patients with non-Hhcy. Furthermore, Hhcy group had a higher proportion of antihypertensive treatment and a lower proportion of hypoglycemic treatment before admission compared with non-Hhcy group. For the specific types of drugs, there was no significantly statistical difference in the use of different types of antihypertensive drugs between the two groups. However, patients with non-Hhcy had a higher proportion of biguanides use than patients with Hhcy (Supplemental Table 1). Moreover, patients with Hhcy had a higher proportion of cortex infarct and a larger infarct volume than patients with non-Hhcy. As for the outcome, the Hhcy group had a higher incidence of poor outcome than the non-Hhcy group (40.9 vs. 29.2%, \( p = 0.022 \)). However, there was no significant difference in the incidence of HT (11.9 vs. 10.6%, \( p = 0.711 \)) and sICH (2.0 vs. 0.9%, \( p = 0.695 \)) between the two groups.

Association Between Hhcy and Clinical Outcome After Thrombolysis

As shown in Table 2, univariate analysis showed that poor outcome was associated with age, atrial fibrillation, hypertension, baseline NIHSS, baseline blood glucose, and bridging therapy. After adjustment for age, atrial fibrillation, hypertension,
hypoglycemic agents/insulin, baseline NIHSS, baseline blood glucose, and bridging therapy, multivariate logistic regression analysis (Figure 2) disclosed that Hhcy was independently associated with an increased risk of poor outcome (OR = 1.760; 95% CI: 1.069–2.896). In addition, we found no significant interaction between Hhcy and hypertension on the clinical outcome after thrombolysis (p = 0.513).

**Association Between Hhcy and HT After Thrombolysis**

Table 3 shows that HT after thrombolysis was related to atrial fibrillation, baseline NIHSS, and bridging therapy. After adjustment for age, atrial fibrillation, baseline NIHSS, and bridging therapy, multivariate logistic regression analysis (Figure 3) disclosed that Hhcy was not associated with the risk of HT after thrombolysis (OR = 1.017; 95% CI: 0.495–2.087). In addition, we found no significant interaction between Hhcy and hypertension on the HT after thrombolysis (p = 0.170).

**DISCUSSION**

This study included a cohort of ischemic stroke patients with intravenous rtPA thrombolysis and attempted to determine the effect of Hhcy on the clinical outcome and HT after thrombolysis. We found that Hhcy was an independent risk factor for poor outcome, but not an independent risk factor for HT after thrombolysis. In addition, we found no significant interaction of Hhcy and hypertension on the clinical outcome or HT after thrombolysis.

Although a small number of studies have already been published, the role of Hhcy in the clinical outcome of ischemic stroke after thrombolysis remains controversial. Ribó et al. first explored this issue in two prospective studies of small sample sizes (44 patients and 77 patients, respectively) and found that plasma homocysteine levels were not associated with the clinical outcome after thrombolysis in ischemic stroke patients (15, 16). However, in a retrospective study of 194 patients with ischemic stroke, Yao and colleagues found that compared with the first quartile (2.26–11.50 µmol/L) of serum homocysteine levels, the fourth quartile (23.85–138.90 µmol/L) was independently associated with an increased risk of poor outcome after thrombolysis (OR = 13.75; 95% CI: 3.57–51.77) (11). These inconsistent results might be caused by small sample sizes. Thus, we conducted this study with a larger sample size and adopted the definition of Hhcy recommended by the American Heart Association and the American Stroke Association Council on stroke to investigate the effect of Hhcy on the clinical outcome after thrombolysis. We found that consistent with the findings of the two retrospective studies described above, Hhcy was an independent risk factor for poor outcome, which provides new proof for the adverse effects of Hhcy on the clinical outcome of ischemic stroke.

The mechanisms of Hhcy’s effect on the clinical outcome of ischemic stroke after thrombolysis are not clear. However, experimental studies have provided some insights into the mechanisms of Hhcy-induced brain injury. It was found that Hhcy can induce excitotoxicity via the glutamate receptor (27). In addition, Hhcy can increase the production of free radicals and inhibit the activity of antioxidant enzymes to cause oxidative stress (27). Furthermore, Hhcy can increase the expression of pro-inflammatory genes in microglia to mediate an inflammatory response (28). Moreover, Hhcy can lead to neuronal death via multiple mechanisms: Hhcy can induce DNA damage, mitochondrial dysfunction, and the stress response of endoplasmic reticulum to cause neural cell apoptosis (29); Hhcy can lead to neuronal death via oxidative damage-mediated autophagy activation (30); Autoxidation of Hhcy metabolites leads to the production of large amounts of H₂O₂ that can induce necrotic cell death (27).

Previous research has found that HT after thrombolysis was associated with rtPA-induced coagulopathy, ischemic injury, reperfusion injury, and disruption of the blood-brain barrier, and the breakdown of blood-brain barrier played a critical role in the development of HT (4, 17, 31). Experimental studies found that Hhcy can lead to endothelial dysfunction, increased expression of matrix metalloproteinase 9, and disruption of the blood-brain barrier (18, 27, 28). Furthermore, a clinical study found that

![Figure 3](https://www.frontiersin.org/articles/10.3389/fneur.2019.00592/full#fig3)
higher serum homocysteine levels were independently associated with an elevated risk of cerebral microbleeds in patients with acute ischemic stroke due to large-artery atherosclerosis (32). These findings imply that Hhcy might increase the risk of HT in ischemic stroke patients with intravenous thrombolysis. However, we did not find a significant association between Hhcy and HT after thrombolysis in this study. To our best knowledge, it is the first study to explore the relationship between Hhcy and HT after thrombolysis. In addition, there was no significantly statistical difference in the incidence of sICH between Hhcy group and non-Hhcy group in the present study. However, previous studies found that patients with Hhcy tended to have a higher incidence of sICH (10, 11). Thus, the association between Hhcy and sICH needs further investigation in the future.

In China, Hhcy is a common comorbidity in hypertensive patients with a proportion of up to 75% (19). Previous studies have noted an interaction between Hhcy and hypertension on some clinical events. For example, a case-control study found a more than multiplicative effect of Hhcy and hypertension on the risk of vascular disease (33). In addition, Fan and colleagues also found that Hhcy and hypertension had a more than multiplicative effect on the baseline stroke severity in patients with first-ever ischemic stroke (34). However, this effect has not been assessed on the clinical outcome or HT in ischemic stroke.

**TABLE 2** Univariate analysis of baseline factors associated with clinical outcome.

| Variables                  | Favorable outcome (n = 349) | Poor outcome (n = 219) | p    |
|----------------------------|-----------------------------|------------------------|------|
| **Demographics**           |                             |                        |      |
| Age (year)                 | 61.1 ± 11.9                 | 64.0 ± 11.8            | 0.005|
| Sex (male)                 | 254 (72.8%)                 | 164 (74.9%)            | 0.579|
| **Vascular risk factors**  |                             |                        |      |
| Cigarette smoking          | 207 (59.3%)                 | 120 (54.8%)            | 0.289|
| Alcohol consumption        | 139 (39.8%)                 | 90 (41.1%)             | 0.764|
| Atrial fibrillation        | 46 (13.2%)                  | 54 (24.7%)             | 0.001|
| Coronary heart disease     | 55 (15.8%)                  | 33 (15.1%)             | 0.825|
| Hypertension               | 196 (56.2%)                 | 142 (64.8%)            | 0.040|
| Diabetes mellitus          | 103 (29.5%)                 | 78 (35.6%)             | 0.129|
| Dyslipidemia               | 220 (63.0%)                 | 133 (60.7%)            | 0.581|
| Previous stroke            | 76 (21.8%)                  | 47 (21.5%)             | 0.929|
| **Previous history of drugs** |                            |                        |      |
| Antihypertensive drugs     | 104 (29.8%)                 | 71 (32.4%)             | 0.510|
| Hypoglycemic agents/insulin| 40 (11.5%)                  | 36 (16.4%)             | 0.090|
| Statins                    | 4 (1.1%)                    | 1 (0.5%)               | 0.654|
| Anti-thrombotic agents     | 37 (10.6%)                  | 30 (13.7%)             | 0.265|
| **Baseline parameters**    |                             |                        |      |
| NIHSS score                | 7 (4–11)                    | 12 (6–15)              | 0.001|
| SBP (mmHg)                 | 156 (138–175)               | 160 (140–176)          | 0.603|
| DBP (mmHg)                 | 90 (80–99)                  | 91 (81–102)            | 0.259|
| Blood glucose (mmol/L)     | 6.78 (5.96–8.67)            | 7.26 (6.38–8.72)       | 0.022|
| Hhcy                       | 269 (77.1%)                 | 186 (84.9%)            | 0.022|
| **Treatment**              |                             |                        |      |
| Time to treat (hour)       | 3.0 (2.4–3.8)               | 3.0 (2.2–3.8)          | 0.623|
| Low-dose thrombolysis      | 97 (27.8%)                  | 60 (27.4%)             | 0.918|
| Bridging therapy           | 27 (7.7%)                   | 27 (12.3%)             | 0.069|

**TABLE 3** Univariate analysis of baseline factors associated with HT.

| Variables                  | Patients without HT (n = 502) | Patients with HT (n = 66) | p    |
|----------------------------|-------------------------------|---------------------------|------|
| **Demographics**           |                               |                           |      |
| Age (year)                 | 61.9 ± 12.0                   | 64.8 ± 10.9               | 0.062|
| Sex (male)                 | 370 (73.7%)                   | 48 (72.7%)                | 0.865|
| **Vascular risk factors**  |                               |                           |      |
| Cigarette smoking          | 290 (57.8%)                   | 37 (56.1%)                | 0.792|
| Alcohol consumption        | 202 (40.2%)                   | 27 (40.9%)                | 0.917|
| Atrial fibrillation        | 73 (14.5%)                    | 27 (40.9%)                | 0.001|
| Hypertension               | 57 (14.9%)                    | 13 (19.7%)                | 0.315|
| Diabetes mellitus          | 161 (32.1%)                   | 20 (30.3%)                | 0.772|
| Dyslipidemia               | 314 (62.5%)                   | 39 (59.1%)                | 0.586|
| Previous stroke            | 106 (21.1%)                   | 17 (25.8%)                | 0.389|
| **Previous history of drugs** |                             |                           |      |
| Antihypertensive drugs     | 154 (30.7%)                   | 21 (31.8%)                | 0.850|
| Hypoglycemic agents/insulin| 70 (13.9%)                    | 6 (9.1%)                  | 0.276|
| Statins                    | 5 (1.0%)                      | 0 (0.0%)                  | 1.000|
| Anti-thrombotic agents     | 56 (11.2%)                    | 11 (16.7%)                | 0.192|
| **Baseline parameters**    |                               |                           |      |
| NIHSS score                | 8 (4–12)                      | 12.5 (8–16)               | 0.001|
| SBP (mmHg)                 | 157.7 ± 26.7                  | 159.2 ± 25.2              | 0.660|
| DBP (mmHg)                 | 90 (80–100)                   | 91.5 (80–99)              | 0.764|
| Blood glucose (mmol/L)     | 7.01 (6.05–8.73)              | 7.24 (6.35–8.64)          | 0.398|
| Hhcy                       | 401 (79.9%)                   | 54 (81.8%)                | 0.711|
| **Treatment**              |                               |                           |      |
| Time to treat (hour)       | 3.0 (2.3–3.8)                 | 2.8 (2.2–3.6)             | 0.444|
| Low-dose thrombolysis      | 142 (28.3%)                   | 15 (22.7%)                | 0.342|
| Bridging therapy           | 35 (7.0%)                     | 19 (28.8%)                | 0.001|

NIHSS, National Institute of Health Stroke Scale; SBP, systolic blood pressure; DBP, diastolic blood pressure; Hhcy, hyperhomocysteinemia.
patients with intravenous thrombolysis. In this study, we did not find significant interaction between Hhcy and hypertension on the clinical outcome or HT after thrombolysis in ischemic stroke patients.

There are some limitations in the present study. First, this study was a retrospective analysis with a limited sample size. Second, the levels of plasma homocysteine were measured after thrombolysis, which might affect the correlation between Hhcy and HT. Third, Hhcy may be caused by genetic factors, physiologic factors, lifestyle factors, various diseases, and drugs (35). However, we did not assess the cause of Hhcy in this study cohort, such as genetic testing. Last, we did not explore the relationship between Hhcy and sICH. Further exploration should be conducted in a multicenter study with a large sample size.

CONCLUSION

We found that Hhcy was an independent risk factor for poor outcome, but not an independent risk factor for HT after thrombolysis in ischemic stroke patients. In addition, there was no significant interaction of Hhcy and hypertension on the clinical outcome or HT after thrombolysis.

DATA AVAILABILITY

The datasets generated for this study are available on request to the corresponding author.

REFERENCES

1. Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, et al. Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. (2013) 381:1987–2015. doi: 10.1016/S0140-6736(13)61097-1
2. Jauch EC, Saver JL, Adams HP Jr., Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. (2013) 44:870–947. doi: 10.1161/STR.0b013e318284056a
3. Powers WJ, Rahbinstein AA, Ackerson T, Adeoye OM, Rambakidis NC, Becker K, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. (2018) 49:e46–110. doi: 10.1161/STR.0b013e3188715152
4. Yaghil S, Willey JZ, Cucchiara B, Goldstein JJ, Gonzalez NR, Khatri P, et al. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. (2017) 48:e343–61. doi: 10.1161/STR.0000000000000152
5. He Y, Li Y, Chen Y, Feng L, Nie Z. Homocysteine level and risk of different stroke types: a meta-analysis of prospective observational studies. Nutr Metab Cardiovasc Dis. (2014) 24:1158–65. doi: 10.1016/j.numecd.2014.05.011
6. Naess H, Nyland H, Idicula T, Waje-Andreassen U. C-reactive protein and homocysteine predict long-term mortality in young ischemic stroke patients. J Stroke Cerebrovasc Dis. (2013) 22:e435–40. doi: 10.1016/j.jstrokecerebrovasdis.2013.04.031
7. Tu WJ, Zhao SJ, Liu TG, Yang DG, Chen H. Combination of high-sensitivity C-reactive protein and homocysteine predicts the short-term outcomes of Chinese patients with acute ischemic stroke. Neurul Res. (2013) 35:912–21. doi: 10.1179/174312813Y.0000000228

ETHICS STATEMENT

This study was approved by the Ethics Review Committee of the First Hospital of Jilin University, and written informed consent was obtained from all participants or their direct relatives.

AUTHOR CONTRIBUTIONS

YL, XS, and YiY were responsible for study design. HJ, Z-NG, L-YZ, JC, YaY, YW, JL, and Q-YH performed the data collection. PZ conducted the data analysis. YL drafted the manuscript. HJ, Z-NG, and PZ helped revise the article. All authors were responsible for data interpretation.

FUNDING

This work was supported by the National Natural Science Foundation of China to YY (Grant No. 81771243) and the Program for JLnundT (2017TD-12) to YY.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2019.00592/full#supplementary-material
activator. *Thromb Haemost.* (2004) 91:1146–51. doi: 10.1160/TH04-02-0097
16. Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Quintana M, et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. *Stroke.* (2004) 35:2123–7. doi: 10.1161/01.STR.0000137608.73660.4c
17. Kim EY, Na DG, Kim SS, Lee KH, Ryoo JW, Kim HK. Prediction of hemorrhagic transformation in acute ischemic stroke: role of diffusion-weighted imaging and early parenchymal enhancement. *AJNR Am J Neuroradiol.* (2005) 26:1050–5.
18. Kamath AE, Chauhan AK, Kisucka J, Dole VS, Loscalzo J, Handy DE, et al. Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. *Blood.* (2006) 107:591–3. doi: 10.1182/blood-2005-06-2506
19. Zhong C, Lv L, Liu C, Zhao L, Zhou M, Sun W, et al. High homocysteine and blood pressure related to poor outcome of acute ischemia stroke in Chinese population. *PLoS ONE.* (2014) 9:e107498. doi: 10.1371/journal.pone.0107498
20. Wang Y, Cui L, Ji X, Dong Q, Zeng J, Wang Y, et al. The China National Stroke Registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. *Int J Stroke.* (2011) 6:355–61. doi: 10.1111/j.1747-4949.2011.00584.x
21. Zhang FL, Xing YQ, Wu YH, Liu HY, Luo Y, Sun MS, et al. The prevalence, awareness, treatment, and control of dyslipidemia in northeast China: a population-based cross-sectional survey. *Lipids Health Dis.* (2017) 16:61. doi: 10.1186/s12944-017-0453-2
22. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. *Circulation.* (1999) 99:178–82. doi: 10.1161/01.CIR.99.1.178
23. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. *Stroke.* (2006) 37:577–617. doi: 10.1161/01.STR.0000199147.30016.74
24. Lin C, Sangha R, Lee J, Corado C, Jalasutram A, Chatterjee N, et al. Infarct location is associated with quality of life after mild ischemic stroke. *Int J Stroke.* (2018) 13:824–31. doi: 10.1177/1747493018738760
25. Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. *Neuroimage.* (2006) 31:1116–28. doi: 10.1016/j.neuroimage.2006.01.015
26. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. *N Engl J Med.* (2008) 359:1317–29. doi: 10.1056/NEJMoa0804656
27. Lehotsky J, Petras M, Koválska M, Tothova B, Drgova A, Kaplan P. Mechanisms involved in the ischemic tolerance in brain: effect of the homocysteine. *Cell Mol Neurobiol.* (2015) 35:7–15. doi: 10.1007/s10537-014-0112-3
28. Weekman EM, Woolums AE, Suddholt TL, Wilcock DM. Hyperhomocysteinemia-induced gene expression changes in the cell types of the brain. *ASN Neuro.* (2017) 9:1759091417742296. doi: 10.1177/1759091417742296
29. Wang L, Tian X. Epigallocatechin-3-gallate protects against homocysteine-induced brain damage in rats. *Planta Med.* (2018) 84:34–41. doi: 10.1055/s-0043-114865
30. Zhao Y, Huang G, Chen S, Gou Y, Dong Z, Zhang X. Homocysteine aggravates cortical neural cell injury through neuronal autophagy overactivation following rat cerebral ischemia-reperfusion. *Int J Mol Sci.* (2016) 17:E1196. doi: 10.3390/ijms17081196
31. Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. *Neurobiol Dis.* (2010) 38:376–85. doi: 10.1016/j.nbd.2010.03.008
32. Wang BR, Ou Z, Jiang T, Zhang YD, Zhao HD, Tian YY, et al. Independent correlation of serum homocysteine with cerebral microbleeds in patients with acute ischemic stroke due to large-artery atherosclerosis. *J Stroke Cerebrovasc Dis.* (2016) 25:2746–51. doi: 10.1016/j.jstrokecerebrovasdis.2016.07.028
33. El-Khairly L, Ueland PM, Refsum H, Graham IM, Vollset SE, European Concerted Action Project. Plasma total cysteine as a risk factor for vascular disease: the European Concerted Action Project. *Circulation.* (2001) 103:2544–9. doi: 10.1161/01.CIR.103.21.2544
34. Fan YL, Zhan R, Dong YF, Huang L, Ji XX, Lu P, et al. Significant interaction of hypertension and homocysteine on neurological severity in first-ever ischemic stroke patients. *J Am Soc Hypertens.* (2018) 12:534–41. doi: 10.1016/j.jsh.2018.03.011
35. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. *Clin Chem.* (2004) 50:3–32. doi: 10.1373/clinchem.2003.021634

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Luo, Jin, Guo, Zhang, Zhang, Chen, Yu, Wang, Liu, He, Sun and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction which does not comply with these terms.